But the company also forecast a 2008 profit at the low end of Wall Street estimates, and analysts took a cautious view on the company’s prospects. Lehman Brothers analyst Richard Silver reaffirmed a “Equal Weight” rating with a $32 price target, citing increasing competition for dermal fillers — used to treat wrinkles — and generic competition for the acne treatment Solodyn. The Food and Drug Administration recently rejected Medicis’ dermal filler Reloxin, citing an incomplete application. Citi analyst Andrew Swanson took a similar position, reaffirming a “Hold” rating and a $22 price target. Meanwhile, RBC Capital Markets analyst Ken Trbovich reaffirmed a “Outperform” rating with a $30 price target, brushing off concerns over Reloxin. read more
Technorati Tags: , analyst, dermal, price, rating, target, acne news
Permanent link to this post (126 words, estimated 30 secs reading time)